Robert Clarke

Prof. Robert Clarke

The Hormel Institute, University of Minnesota, Minneapolis, Minnesota, USA
orcid

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
RCRobert Clarke
Robert Clarke
HRHabtom W. Ressom
Habtom W. Ressom
AWAntai Wang
Antai Wang
JXJianhua Xuan
Jianhua Xuan
MLMinetta C. Liu
Minetta C. Liu
YWYue Wang
Yue Wang

13 July 2003 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MJMichael D Johnson
Michael D Johnson
NKNicholas Kenney
Nicholas Kenney
ASAdriana Stoica
Adriana Stoica
LHLeena Hilakivi-Clarke
Leena Hilakivi-Clarke
BSBaljit Singh
Baljit Singh
MMMary Beth Martin
Mary Beth Martin

1 March 1992 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
ETErik Walter Thompson
Erik Walter Thompson
SPSoonmyoung Paik
Soonmyoung Paik
NBNils Brünner
Nils Brünner
CSConnie L. Sommers
Connie L. Sommers
GZGerhard Zugmaier
Gerhard Zugmaier
RDRobert B. Dickson
Robert B. Dickson

20 October 2003 in Oncogene
Verified
Journal Article
Closed access
RCRobert Clarke
Robert Clarke
MLMinetta C Liu
Minetta C Liu
KBKerrie B Bouker
Kerrie B Bouker
ZGZhiping Gu
Zhiping Gu
RLRichard Y Lee
Richard Y Lee
LHLeena A Hilakivi-Clarke
Leena A Hilakivi-Clarke

5 April 2006 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
BTBruce J. Trock
Bruce J. Trock
LHLeena Hilakivi-Clarke
Leena Hilakivi-Clarke
RCRobert Clarke
Robert Clarke
Background: High intake of soy foods has been proposed to contribute to the low breast cancer risk in Asian countries. However, results of epidemiologic studies of this association are highly variable, and experimental data suggest that soy constituents can be estrogenic and potentially risk enhancing. Thus, rigorous evaluation of available epidemiologic data is necessary before appropriate recommendations can be made, especially for women at high risk of breast cancer or those who have survived the disease. Methods: We performed a meta-analysis of 18 epidemiologic studies (12 case–control and six cohort or nested case–control) published from 1978 through 2004 that examined soy exposure and breast cancer risk. Pooled relative risk estimates were based on either the original soy exposure measure defined in each study or on an estimate of daily soy protein intake. Results: Risk estimates, levels and measures of soy exposure, and control for confounding factors varied considerably across studies. In a pooled analysis, among all women, high soy intake was modestly associated with reduced breast cancer risk (odds ratio [OR] = 0.86, 95% confidence interval [CI] = 0.75 to 0.99); the association was not statistically significant among women in Asian countries (OR = 0.89, 95% CI = 0.71 to 1.12). Among the 10 studies that stratified by menopausal status the inverse association between soy exposure and breast cancer risk was somewhat stronger in premenopausal women (OR = 0.70, 95% CI = 0.58 to 0.85) than in postmenopausal women (OR = 0.77, 95% CI = 0.60 to 0.98); however, eight studies did not provide menopause-specific results, six of which did not support an association. When exposure was analyzed by soy protein intake in grams per day, a statistically significant association with breast cancer risk was seen only among premenopausal women (OR = 0.94, 95% CI = 0.92 to 0.97). Conclusions: Soy intake may be associated with a small reduction in breast cancer risk. However, this result should be interpreted with caution due to potential exposure misclassification, confounding, and lack of a dose response. Given these caveats and results of some experimental studies that suggest adverse effects from soy constituents, recommendations for high-dose isoflavone supplementation to prevent breast cancer or prevent its recurrence are premature.

2 July 1997 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
BTBruce J. Trock
Bruce J. Trock
FLFabio Leonessa
Fabio Leonessa
RCRobert Clarke
Robert Clarke
Background: P-glycoprotein (gp170; encoded by the MDR1 gene [also known as PGY1]) is a membrane protein capable of exporting a variety of anticancer drugs from cells. MDR1/ gp170 expression has been studied in breast cancer, but the prevalence of this expression and its role in breast tumor drug resistance are unclear. Purpose: We conducted a critical review and meta-analysis of studies examining MDR1/ gp170 expression in breast cancer to estimate the likely prevalence and clinical relevance of this expression. We also explored reasons for differences in the findings from individual studies. Methods: Published papers on MDR1/gp170 expression in breast cancer were identified by searching several literature databases and reviewing the bibliographies of identified papers. Variability across the studies in the proportion of tumors expressing MDR1/gp170 was assessed by use of chi-squared tests of homogeneity, weighted means, and weighted linear regression. Pooled relative risks (RRs) for the association between the induction of MDR1/gp170 expression and prior chemotherapy and associations between MDR1/gp170 expression and several clinical outcomes were estimated by use of Mantel-Haenszel methods. Heterogeneity among the pooled RRs was explored by use of chisquared tests. Reported P values are two-sided. Results: Thirty-one studies were identified and evaluated. The proportion of breast tumors expressing MDR1/gp170 in all of the studies was 41.2%, but there was substantial heterogeneity in the values across individual studies (P<.0001). Regression analyses demonstrated that a considerable portion of the observed heterogeneity was a consequence of the change, over time, from RNA hybridization-based assays to immunohistochemistry-based assays of MDR1/gp170 expression. Measuring MDR1/gp170 expression before versus after chemotherapy and use of cytotoxic drugs that are not substrates for gp170 also contributed to the heterogeneity. Treatment with chemotherapeutic drugs or hormonal agents was associated with an increase in the proportion of tumors expressing MDR1/gp170 (RR = 1.77; 95% confidence interval [CI] = 1.46-2.15). Patients with tumors expressing MDR1/gp170 were three times more likely to fail to respond to chemotherapy than patients whose tumors were MDR1/ gp170 negative (RR = 3.21; 95% CI = 2.28-4.51); this RR increased to 4.19 (95% CI = 2.71-6.47) when considering only patients whose tumor expression of MDR1/gp170 was measured after chemotherapy. MDR1/gp170 expression was not associated with lymph node metastases, estrogen receptor status, tumor size, tumor grade, or tumor histology. Conclusions and Implications: MDR1/gp170 expression in breast tumors is associated with treatment and with a poor response to chemotherapy. The data are consistent with a contributory role for MDR1/gp170 in the multidrug resistance in some breast tumors.